CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 500 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Longdaysin
CAS:<p>Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 μM). It also can inhibit ERK2 (IC50: 52 μM).</p>Fórmula:C16H16F3N5Pureza:99.97%Forma y color:SolidPeso molecular:335.33TC11
CAS:<p>TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) is a potent inhibitor of tumor cell proliferation and an inducer of apoptosis</p>Fórmula:C20H22N2O2Pureza:97.86%Forma y color:SolidPeso molecular:322.4LY2857785
CAS:<p>LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM).</p>Fórmula:C26H36N6OPureza:99.68%Forma y color:Solid PowderPeso molecular:448.6BS194
CAS:<p>BS194 is as a potent cyclin-dependent protein kinases (CDKs) inhibitor.</p>Fórmula:C20H27N5O3Pureza:99.85%Forma y color:SolidPeso molecular:385.46Palbociclib
CAS:<p>Palbociclib is an oral CDK4/6 inhibitor, halts Rb phosphorylation, arrests cell cycle, and curbs tumor growth.</p>Fórmula:C24H29N7O2Pureza:98% - 99.9%Forma y color:SolidPeso molecular:447.53OTS964 hydrochloride
CAS:<p>OTS964 hydrochloride (OTS964) is a potent and selective TOPK inhibitor with potential anticancer activity.</p>Fórmula:C23H24N2O2S·HClPureza:96.5% - 98.03%Forma y color:SolidPeso molecular:428.97NU2058
CAS:<p>NU2058 (O(6)-Cyclohexylmethylguanine) is a guanine-based CDK inhibitor, also inhibits DNA topoisomerase II ATPase activity.</p>Fórmula:C12H17N5OPureza:99.34% - 99.92%Forma y color:SolidPeso molecular:247.3Aminopurvalanol A
CAS:<p>Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1</p>Fórmula:C19H26ClN7OPureza:99.73%Forma y color:SolidPeso molecular:403.91Indirubin-3′-oxime
CAS:<p>Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.</p>Fórmula:C16H11N3O2Pureza:98.34%Forma y color:SolidPeso molecular:277.28SNS-032
CAS:<p>SNS-032 (BMS-387032) is a selective inhibitor of CDK2 and is 10- and 20-fold selective over CDK1/CDK4. SNS-032 is sensitive to CDK7/9, and no effect on CDK6.</p>Fórmula:C17H24N4O2S2Pureza:98.27% - 99.91%Forma y color:SolidPeso molecular:380.53NVP-LCQ195
CAS:<p>NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).</p>Fórmula:C17H19Cl2N5O4SPureza:99.56% - 99.85%Forma y color:SolidPeso molecular:460.33LY3177833
CAS:<p>LY3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM)</p>Fórmula:C16H12FN5OPureza:99.87%Forma y color:SolidPeso molecular:309.3Abemaciclib methanesulfonate
CAS:<p>Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).</p>Fórmula:C27H32F2N8·CH4O3SPureza:98.69% - 99.44%Forma y color:SolidPeso molecular:602.7Cucurbitacin E
CAS:<p>Cucurbitacin E, from Cucumic melo, inhibits cyclin B1/CDC2, and has neuroprotective, anti-proliferative, anti-cancer, and pain relief properties.</p>Fórmula:C32H44O8Pureza:98.88% - 99.87%Forma y color:SolidPeso molecular:556.69KB-0742 dihydrochloride
CAS:<p>KB-0742 dihydrochloride is a potent, selective and orally inhibitor of CDK9.</p>Fórmula:C16H27Cl2N5Pureza:99.79%Forma y color:SolidPeso molecular:360.33BMS-265246
CAS:<p>BMS-265246 is a potent and selective CDK1/2 inhibitor.</p>Fórmula:C18H17F2N3O2Pureza:99.25% - 99.57%Forma y color:SolidPeso molecular:345.34HQ461
CAS:<p>HQ461, a molecular glue, boosts CDK12-DDB1 binding, lowers cyclin K, impedes CDK12 phosphorylation, hinders DNA repair genes, and induces cell death.</p>Fórmula:C15H15N5OS2Pureza:98.11%Forma y color:SolidPeso molecular:345.44AT7519 Hydrochloride
CAS:<p>AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.</p>Fórmula:C16H18Cl3N5O2Pureza:99.66% - 99.9%Forma y color:SolidPeso molecular:418.71NG 52
CAS:<p>NG 52 (NG-52) is a cell-permeable, reversible, and ATP-compatible inhibitor of the cell cycle-regulating kinase Cdc28p and the related Pho85p kinase.</p>Fórmula:C16H19ClN6OPureza:98% - 99.34%Forma y color:SolidPeso molecular:346.81THZ1
CAS:<p>THZ1 (CDK7 inhibitor) is a selective inhibitor of CDK7, binding to the Cys residue located at the outer end of the classical kinase domain. Cost-effective and quality-assured.</p>Fórmula:C31H28ClN7O2Pureza:95.09% - 99.27%Forma y color:SolidPeso molecular:566.05Bromosporine
CAS:<p>Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.</p>Fórmula:C17H20N6O4SPureza:99.65% - 99.79%Forma y color:SolidPeso molecular:404.44Briciclib
CAS:<p>Briciclib (ON 014185) is a small molecule that suppresses cyclin D1 accumulation in Y cells.</p>Fórmula:C19H23O10PSPureza:98% - 99.84%Forma y color:SolidPeso molecular:474.42AG-494
CAS:<p>AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.</p>Fórmula:C16H12N2O3Pureza:98.69%Forma y color:SolidPeso molecular:280.28PHA-767491
CAS:<p>PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.</p>Fórmula:C12H11N3OPureza:99.49% - >99.99%Forma y color:SolidPeso molecular:213.24ON-013100
CAS:<p>ON-013100 is an antineoplastic drug. ON-013100 also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.</p>Fórmula:C19H22O7SPureza:98.27%Forma y color:SolidPeso molecular:394.44MLS-573151
CAS:<p>MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM).</p>Fórmula:C21H19N3O2SPureza:98.80%Forma y color:SolidPeso molecular:377.46Senexin A
CAS:<p>Senexin A is an effective and selective CDK8 inhibitor that also inhibits CDK19 with Kd values of 0.83 microns and 0.31 microns, respectively.</p>Fórmula:C17H14N4Pureza:99.74%Forma y color:SolidPeso molecular:274.32LDC-4297 HCl (1453834-21-3(free base))
<p>LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.</p>Fórmula:C23H29ClN8OPureza:100%Forma y color:SolidPeso molecular:469.02FIT-039
CAS:<p>FIT-039 is a selective and ATP-competitive, orally active inhibitor of CDK9( IC50 : 5.8 μM;CDK9/cyclin T1).</p>Fórmula:C17H18FN3SPureza:98.61%Forma y color:SolidPeso molecular:315.41ON123300
CAS:<p>ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).</p>Fórmula:C24H27N7OPureza:99.22% - 99.53%Forma y color:SolidPeso molecular:429.52Ribociclib
CAS:<p>Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).</p>Fórmula:C23H30N8OPureza:97.91% - >99.99%Forma y color:SolidPeso molecular:434.54Milciclib
CAS:<p>Milciclib (PHA-848125) is a potent CDK2 inhibitor with a 45 nM IC50, selective over CDK1/2/4/5/7. In Phase 2 trials.</p>Fórmula:C25H32N8OPureza:99.28%Forma y color:SolidPeso molecular:460.57YKL-5-124
CAS:<p>YKL-5-124, a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for CDK7/Mat1/CycH, CDK2 and CDK9 respectively, displays</p>Fórmula:C28H33N7O3Pureza:99.36%Forma y color:SolidPeso molecular:515.61BGG463
CAS:<p>BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.</p>Fórmula:C30H29F3N6O3Pureza:95.05% - >99.99%Forma y color:SolidPeso molecular:578.58Ro-3306
CAS:<p>RO-3306: ATP-competitive CDK1 inhibitor, Ki 20 nM, >15x more selective than other human kinases.</p>Fórmula:C18H13N3OS2Pureza:97.67% - 99.79%Forma y color:SolidPeso molecular:351.45KenPaullone
CAS:<p>KenPaullone (9-Bromopaullone), a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation.</p>Fórmula:C16H11BrN2OPureza:97.14% - 98.99%Forma y color:Tan SolidPeso molecular:327.18NU6027
CAS:<p>NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-</p>Fórmula:C11H17N5O2Pureza:98.36%Forma y color:SolidPeso molecular:251.29Abemaciclib
CAS:<p>Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity.</p>Fórmula:C27H32F2N8Pureza:99.43% - 99.87%Forma y color:SolidPeso molecular:506.59NSC23005 Sodium
CAS:<p>NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.</p>Fórmula:C13H16NNaO4SPureza:99.64%Forma y color:SolidPeso molecular:305.32BSJ-4-116
CAS:<p>BSJ-4-116: potent, selective CDK12 PROTAC, IC50 = 6 nM; downregulates DDR genes, induces premature transcription termination.</p>Fórmula:C40H49ClN8O8SPureza:99.09%Forma y color:SolidPeso molecular:837.38ALSTERPAULLONE
CAS:<p>Alsterpaullone is a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells Through Apoptosis-Inducing Effec</p>Fórmula:C16H11N3O3Pureza:99.8%Forma y color:SolidPeso molecular:293.28BS-181 hydrochloride
CAS:<p>BS-181 hydrochloride (BS-181 HCl) is a highly selective CDK7 inhibitor with IC50 of 21 nM.</p>Fórmula:C22H32N6·HClPureza:99.21%Forma y color:SolidPeso molecular:416.99JNJ-7706621
CAS:<p>JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2.</p>Fórmula:C15H12F2N6O3SPureza:99.1% - 99.85%Forma y color:SolidPeso molecular:394.36MC180295
CAS:<p>MC180295 ((rel)-MC180295) is a novel potent, highly selective CDK9 inhibitor (IC50: 5 nM), displays >22-fold selectivity over other CDKs.</p>Fórmula:C17H18N4O3SPureza:99.84%Forma y color:SolidPeso molecular:358.41ML167
CAS:<p>ML167 (CID44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.</p>Fórmula:C19H17N3O3Pureza:99.82% - >99.99%Forma y color:SolidPeso molecular:335.36R547
CAS:<p>R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM.</p>Fórmula:C18H21F2N5O4SPureza:90% - 99.64%Forma y color:SolidPeso molecular:441.45Bohemine
CAS:<p>Bohemine is a cyclin-dependent kinase inhibitor.</p>Fórmula:C18H24N6OPureza:99.09% - 99.53%Forma y color:SolidPeso molecular:340.42THZ531
CAS:<p>THZ531 is a covalent inhibitor of both CDK12(IC50=158 nM) and CDK13(IC50=69 nM).</p>Fórmula:C30H32ClN7O2Pureza:97.17% - 99.86%Forma y color:SolidPeso molecular:558.07PHA-793887
CAS:<p>PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.</p>Fórmula:C19H31N5O2Pureza:98.02% - >99.99%Forma y color:SolidPeso molecular:361.48AUZ 454
CAS:<p>AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 50/18.6/15.4/9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.</p>Fórmula:C24H26F3N7O2Pureza:99.59%Forma y color:SolidPeso molecular:501.5AMG 925
CAS:<p>AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.</p>Fórmula:C26H29N7O2Pureza:99.75%Forma y color:SolidPeso molecular:471.55CID44216842
CAS:<p>CID44216842 is a potent Cdc42-selective inhibitor with EC50: 1.0μM (WT), 1.2μM (Q61L) in GTP assay; 0.3μM (WT), 0.5μM (Q61L) in GDP assay. Use as a probe.</p>Fórmula:C22H20BrN3O3SPureza:99.66%Forma y color:SolidPeso molecular:486.38CVT-313
CAS:<p>CVT-313 (NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor.</p>Fórmula:C20H28N6O3Pureza:97.46% - 97.97%Forma y color:SolidPeso molecular:400.47GSK 3 Inhibitor IX
CAS:<p>GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex.</p>Fórmula:C16H10BrN3O2Pureza:98% - 99.72%Forma y color:SolidPeso molecular:356.17Purvalanol B
CAS:<p>Purvalanol B (NG 95) is a CDK inhibitor that inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively)</p>Fórmula:C20H25ClN6O3Pureza:98.95%Forma y color:SolidPeso molecular:432.9Palbociclib monohydrochloride
CAS:<p>Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6, with no inhibition against a panel of 36 additional protein kinases</p>Fórmula:C24H29N7O2·HClPureza:99.73% - >99.99%Forma y color:SolidPeso molecular:483.99Toyocamycin
CAS:<p>Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (</p>Fórmula:C12H13N5O4Pureza:98.1% - 98.17%Forma y color:SolidPeso molecular:291.26Wogonin
CAS:<p>Wogonin (Vogonin) is a cell-permeable and orally available flavonoid that displays anti-inflammatory and anticancer properties.</p>Fórmula:C16H12O5Pureza:98% - 99.8%Forma y color:Yellow CrystalPeso molecular:284.26Palbociclib Isethionate
CAS:<p>Palbociclib Isethionate (PD 0332991 isethionate) 是一种高选择性的CDK4/6抑制剂，IC50为11 nM 和16 nM。它对一组 36 种额外的蛋白激酶没有抑制作用。</p>Fórmula:C24H29N7O2·C2H6O4SPureza:99.01% - 99.27%Forma y color:SolidPeso molecular:573.66SU9516
CAS:<p>SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also has inhibitory effects on CDK1 and CDK4, with IC50s of 40 nM and 200 nM, respectively.</p>Fórmula:C13H11N3O2Pureza:99.34% - 99.87%Forma y color:SolidPeso molecular:241.25BI-1347
CAS:<p>BI-1347 is a potent, selective inhibitor of CDK8/cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model.</p>Fórmula:C22H20N4OPureza:96.7% - 99.63%Forma y color:SolidPeso molecular:356.42SRI-29329
CAS:<p>SRI-29329 is a potent, specific inhibitor of CDC-like kinase (with IC50 of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively).</p>Fórmula:C20H26ClN7Pureza:99.18%Forma y color:SolidPeso molecular:399.92NSC23005
CAS:<p>NSC23005 sodium is a p18INK inhibitor with potently promoted hematopoietic stem cell (HSC) expansion (ED50: 5.21 nM).</p>Fórmula:C13H17NO4SPureza:>99.99%Forma y color:SolidPeso molecular:283.34AT7519
CAS:<p>AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.</p>Fórmula:C16H17Cl2N5O2Pureza:98.88% - 99.65%Forma y color:SolidPeso molecular:382.24(E/Z)-TG003
CAS:<p>(E/Z)-TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor.</p>Fórmula:C13H15NO2SPureza:98% - 99.04%Forma y color:SolidPeso molecular:249.33TP-353
CAS:<p>TP-353 (EOS-61973) is a CDK7 inhibitor.</p>Fórmula:C35H30FNO3Pureza:99.12%Forma y color:SolidPeso molecular:531.62Trilaciclib
CAS:<p>Trilaciclib is a short-acting, orally effective CDK4/6 inhibitor with IC₅₀ values of 1 nM and 4 nM respectively. enhances antitumour immunity.</p>Fórmula:C24H30N8OPureza:99.624%Forma y color:SolidPeso molecular:446.55AZ5576
CAS:<p>AZ5576 is a potent and highly selective CDK9 inhibitor. AZ5576 can be used for the research of Hematological Malignancy [1].</p>Fórmula:C21H24FN3O3Pureza:99.88%Forma y color:SoildPeso molecular:385.43CDK12-IN-5
CAS:<p>CDK12-IN-5 is a potent CDK12 inhibitor with potential anticancer and antitumor activity, and can be used orally in the study of breast and ovarian cancer.</p>Fórmula:C18H15F5N8OPureza:99.37%Forma y color:SolidPeso molecular:454.36LSN2839567
CAS:<p>LSN2839567 (Abemaciclib metabolite M2) is a CDK4 and CDK6 inhibitor with anticancer activity, inhibits CDK9, and can be used in breast cancer research.</p>Fórmula:C25H28F2N8Pureza:99.14%Forma y color:SolidPeso molecular:478.54(R)-(+)-O-Demethylbuchenavianine
CAS:<p>(R)-(+)-O-Demethylbuchenavianine is a cyclin-dependent kinase (CDK) inhibitor. It inhibits CDK1, CDK5, glycogen synthase kinase 3 (GSK3), cdc2-like kinase (CLK1), and dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) with IC50 values of 1.1 μM, 0.95 μM, >10 μM, >10 μM, and >10 μM, respectively.</p>Fórmula:C21H21NO4Forma y color:SolidPeso molecular:351.40Riviciclib hydrochloride
CAS:<p>Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.</p>Fórmula:C21H20ClNO5·HClPureza:99.51%Forma y color:SolidPeso molecular:438.3XL413
CAS:<p>XL-413 is an oral CDC7 kinase inhibitor, potentially blocking DNA replication, mitosis, and cancer cell growth.</p>Fórmula:C14H12ClN3O2Pureza:98.40% - >99.99%Forma y color:SolidPeso molecular:289.72MFH290
CAS:<p>MFH290 is a selective CDK12/13 inhibitor, covalently bonding with CDK12 Cys-1039, blocks Pol II CTD phosphorylation, and enhances olaparib's efficacy.</p>Fórmula:C26H31N5O3S2Forma y color:SolidPeso molecular:525.69CDK2-IN-13
CAS:<p>CDK2-IN-13: Potent CDK2 inhibitor, arrests cell cycle, induces apoptosis, IC50=12 µM, used in cancer research.</p>Fórmula:C13H12ClN5Forma y color:SoildPeso molecular:273.72CDK8-IN-4
CAS:<p>CDK8-IN-4 is an inhibitor of CDK8 (IC50: 0.2 nM).</p>Fórmula:C20H18N4OForma y color:SolidPeso molecular:330.38CDK12-IN-3
CAS:<p>CDK12-IN-3 is a CDK12 inhibitor with anti-tumor activity and can be used for the study of malignant tumors.</p>Fórmula:C23H28F2N8OPureza:99.85%Forma y color:SolidPeso molecular:470.52Cdc7-IN-5
CAS:<p>Cdc7-IN-5: potent Cdc7 serine-threonine kinase inhibitor, critical for starting DNA replication.</p>Fórmula:C25H23N3O5Pureza:97.15%Forma y color:SolidPeso molecular:445.47Cdc7-IN-9
CAS:<p>Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].</p>Fórmula:C15H17N5OSForma y color:SolidPeso molecular:315.39SNX2-1-108
CAS:<p>SNX2-1-108 is a selective CDK8 and CDK19 inhibitor.</p>Fórmula:C21H16N4Pureza:98%Forma y color:SolidPeso molecular:324.38Metralindole HCl
CAS:<p>Metralindole is a reversible monoamine oxidase A (RIMA) inhibitor, it was investigated as a potential antidepressant.</p>Fórmula:C15H18ClN3OPureza:98%Forma y color:SolidPeso molecular:291.78CDK7-IN-15
CAS:<p>CDK7-IN-15, a pyrimidine-based potent CDK7 inhibitor, shows promise for various cancers with defective transcription.</p>Fórmula:C21H24F4N6OSForma y color:SolidPeso molecular:484.51BAY-958
CAS:<p>BAY-958 is a potent and selective inhibitor of PTEFb/CDK9.</p>Fórmula:C17H16FN5O3SPureza:98%Forma y color:SolidPeso molecular:389.4EGFR/CDK2-IN-1
CAS:<p>EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application in</p>Fórmula:C19H12BrClO2Forma y color:SolidPeso molecular:387.65CDK7-IN-10
CAS:<p>CDK7-IN-10: CDK7 inhibitor, IC50<100 nM, may hinder cell growth, induce apoptosis. (Patent WO2021016388A1, I-1)</p>Fórmula:C29H35N7O3Forma y color:SolidPeso molecular:529.63CDK7-IN-16
CAS:<p>CDK7-IN-16, a potent CDK7 inhibitor (IC50: 1-10 nM), is used in cancer research with transcription defects.</p>Fórmula:C19H21F3N6O2SForma y color:SolidPeso molecular:454.47Ipivivint
CAS:<p>Ipivivint: orally active, potent CLK inhibitor; hinders CLK1, CLK2, & CLK3; curbs Wnt signaling & SRSF phosphorylation for cancer research.</p>Fórmula:C26H21FN8Forma y color:SolidPeso molecular:464.5NSC 693868
CAS:<p>CDKs and GSK-3 inhibitor</p>Fórmula:C9H7N5Pureza:98%Forma y color:SolidPeso molecular:185.19Atuveciclib S-Enantiomer
CAS:<p>Atuveciclib S-Enantiomer is a (S)-form of BAY-1143572; a potent, selective CDK9 inhibitor with an IC50 of 16 nM.</p>Fórmula:C18H18FN5O2SPureza:98%Forma y color:SolidPeso molecular:387.43CDK8-IN-6
CAS:<p>CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers.</p>Fórmula:C26H37ClN2Forma y color:SolidPeso molecular:413.04CDK4/6-IN-14
CAS:<p>CDK4/6-IN-14: potent CDK4/6 inhibitor, IC50s 10/16 nM, >60-fold selectivity over CDKs 1/2/7/9, selective across 205 kinases.</p>Fórmula:C24H27ClFN7OForma y color:SolidPeso molecular:483.97KH-CB19
CAS:<p>KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).</p>Fórmula:C15H13Cl2N3O2Forma y color:SolidPeso molecular:338.19Cdc7-IN-14
CAS:<p>Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 < 1 nM, promising for cancer research.</p>Fórmula:C18H20N4O2SForma y color:SolidPeso molecular:356.44CDK9-IN-15
CAS:<p>CDK9-IN-15: potent CDK9 inhibitor, blocks P-TEFb phosphorylation, inhibits transcription, reduces mRNA, induces tumor cell apoptosis.</p>Fórmula:C16H11N3OSPureza:97.24%Forma y color:SolidPeso molecular:293.34CDK-IN-10
CAS:<p>CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.</p>Fórmula:C18H18N4O2Pureza:97.07%Forma y color:SolidPeso molecular:322.36CLK1-IN-2
<p>CLK1-IN-2: Metabolically stable, Clk1-selective inhibitor; IC50=1.7nM; useful in tumor, Duchenne MD, HIV-1, influenza research.</p>Fórmula:C16H12Cl2N2O2SForma y color:SolidPeso molecular:367.25XIE18-6
CAS:<p>XIE18-6 is a novel INK4C inhibitor that blocks p18 activity and promotes ex vivo expansion of human and murine hematopoietic stem cells.</p>Fórmula:C18H15NO6SPureza:99.712%Forma y color:SolidPeso molecular:373.38NSC 625987
CAS:<p>Cyclin-dependent kinase (cdk) 4 inhibitor</p>Fórmula:C15H13NO2SPureza:98%Forma y color:SolidPeso molecular:271.33ARN22089
CAS:<p>ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.</p>Fórmula:C23H27N5Pureza:98.37%Forma y color:SolidPeso molecular:373.49CDK8/19-IN-51
CAS:<p>CDK8/19-IN-51 is a CDK8 and CDK19 inhibitor with anticancer activity, used in research on colorectal and gastric cancers.</p>Fórmula:C23H22N6O2Pureza:98.65% - 99.62%Forma y color:SoildPeso molecular:414.46Cdc7-IN-1
CAS:<p>Cdc7-IN-1: selective ATP-competitive Cdc7 kinase inhibitor; IC50 0.6 nM at 1mM ATP; induces cancer cell death.</p>Fórmula:C21H16ClN3O4Forma y color:SolidPeso molecular:409.82CDK9-IN-14
CAS:<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Fórmula:C21H23F2N3O4Forma y color:SolidPeso molecular:419.42CLK1/2-IN-3
CAS:<p>CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.</p>Fórmula:C21H21N5O2Pureza:99.04%Forma y color:SolidPeso molecular:375.42THZ1-R
CAS:<p>THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.</p>Fórmula:C31H30ClN7O2Pureza:98%Forma y color:SolidPeso molecular:568.07CLK1-IN-1
CAS:<p>CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).</p>Fórmula:C24H16FN5OForma y color:SolidPeso molecular:409.42CDK12-IN-E9
CAS:<p>CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.</p>Fórmula:C24H30N6O2Forma y color:SolidPeso molecular:434.53Cdc7-IN-17
CAS:<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Fórmula:C13H15N5OSForma y color:SolidPeso molecular:289.36AS2863619 free base
CAS:<p>AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.</p>Fórmula:C16H12N8OForma y color:SolidPeso molecular:332.32Cdc7-IN-4
CAS:<p>Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C22H24F3N5O4Pureza:98%Forma y color:SolidPeso molecular:479.45K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Fórmula:C15H13F2N7O2S2Pureza:99.12%Forma y color:SolidPeso molecular:425.44CDK8-IN-7
CAS:<p>CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.</p>Fórmula:C30H40N2Forma y color:SolidPeso molecular:428.65Cdc7-IN-15
CAS:<p>Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].</p>Fórmula:C12H14N4OSForma y color:SolidPeso molecular:262.33CP681301
CAS:<p>CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.</p>Fórmula:C17H22N4OForma y color:SolidPeso molecular:298.38MDK6204
CAS:<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Fórmula:C20H20N6OPureza:98%Forma y color:SolidPeso molecular:360.41BSJ-01-175
CAS:<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Fórmula:C30H33ClN6O2Forma y color:SolidPeso molecular:545.08Indirubin-3'-monoxime-5-sulphonic acid
CAS:<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Fórmula:C16H11N3O5SPureza:98%Forma y color:SolidPeso molecular:357.34CDK7-IN-13
CAS:<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Fórmula:C20H23F3N6OSPureza:99.22%Forma y color:SolidPeso molecular:452.5P18IN003
CAS:<p>P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of</p>Fórmula:C17H16N2O3Pureza:98.77%Forma y color:SolidPeso molecular:296.32CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Fórmula:C30H26N6O3Forma y color:SolidPeso molecular:518.57FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Fórmula:C25H28F2N8Forma y color:SolidPeso molecular:478.54BS-181
CAS:<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Fórmula:C22H32N6Pureza:98%Forma y color:SolidPeso molecular:380.53CDK4/6-IN-12
CAS:<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Fórmula:C12H10N6Forma y color:SolidPeso molecular:238.25CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82CCT068127
CAS:<p>CCT068127 is a potent CDK2 and CDK9 inhibitor.</p>Fórmula:C19H27N7OForma y color:SolidPeso molecular:369.46(S)-CR8
CAS:<p>(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.</p>Fórmula:C24H29N7OForma y color:SolidPeso molecular:431.53CDK7-IN-8
CAS:<p>CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.</p>Fórmula:C25H38N8O3Forma y color:SolidPeso molecular:498.62EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Forma y color:SolidPeso molecular:479.57Aloisine A
CAS:<p>Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.</p>Fórmula:C16H17N3OPureza:98%Forma y color:SolidPeso molecular:267.33TP1287
CAS:<p>TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.</p>Fórmula:C21H21ClNO8PForma y color:SolidPeso molecular:481.82Indirubin-5-sulfonate
CAS:<p>Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.</p>Fórmula:C16H10N2O5SPureza:98%Forma y color:SolidPeso molecular:342.33Crozbaciclib fumarate
CAS:<p>Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.</p>Fórmula:C32H34F2N6O4Forma y color:SolidPeso molecular:604.65CDK7-IN-12
CAS:<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Fórmula:C20H19F3N6Forma y color:SolidPeso molecular:400.4CDK1-IN-1
CAS:<p>CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.</p>Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.5CDK4/6-IN-9
CAS:<p>CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.</p>Fórmula:C22H23FN8Forma y color:SolidPeso molecular:418.47Cdc7-IN-13
CAS:<p>Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].</p>Fórmula:C18H20N4O2SForma y color:SolidPeso molecular:356.44Ulecaciclib
CAS:<p>Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).</p>Fórmula:C25H33FN8SForma y color:SolidPeso molecular:496.65FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49JTK-101
CAS:<p>JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.</p>Fórmula:C25H23N3O3Forma y color:SolidPeso molecular:413.47(E/Z)-BIO-acetoxime
CAS:<p>(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.</p>Fórmula:C18H12BrN3O3Forma y color:SolidPeso molecular:398.21(S)-LY3177833 hydrate
CAS:<p>(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.</p>Fórmula:C16H14FN5O2Forma y color:SolidPeso molecular:327.31RP-106
CAS:<p>RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.</p>Fórmula:C17H19N3OPureza:98%Forma y color:SolidPeso molecular:281.35PKC-9
CAS:<p>PKC-9 is a PKC-zeta inhibitor 9.</p>Fórmula:C25H25N7Forma y color:SolidPeso molecular:423.51CDK4/6-IN-7
CAS:<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Fórmula:C18H18ClN5O3Forma y color:SolidPeso molecular:387.82Cdc7-IN-3
CAS:<p>Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.</p>Fórmula:C20H22N4O5Pureza:98%Forma y color:SolidPeso molecular:398.41CDK7-IN-2
CAS:<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Fórmula:C26H39N7O3Forma y color:SolidPeso molecular:497.63EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Forma y color:SolidPeso molecular:451.56CDK5 inhibitor 20-223
CAS:<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Fórmula:C19H19N3OForma y color:SolidPeso molecular:305.37FN-1501-propionic acid
CAS:<p>FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.</p>Fórmula:C25H27N9O4Pureza:98%Forma y color:SolidPeso molecular:517.54EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Fórmula:C23H20N4O5S2Forma y color:SolidPeso molecular:496.56CDK8-IN-10
CAS:<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Fórmula:C25H15ClF3N5O3Forma y color:SolidPeso molecular:525.87CDK4/6-IN-8
CAS:<p>CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).</p>Fórmula:C18H18N6O5Forma y color:SolidPeso molecular:398.37AS-0141
CAS:<p>AS-0141 (Cdc7-IN-6) 是一种有效的 Cdc7 激酶抑制剂 (IC50=4 nM)，具有抗肿瘤活性。Cdc7 是一种丝氨酸苏氨酸蛋白激酶酶，在细胞周期中对 DNA 复制的启动至关重要。</p>Fórmula:C21H22F3N5O4Pureza:99.97%Forma y color:SolidPeso molecular:465.43Ryuvidine
CAS:<p>Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.</p>Fórmula:C15H12N2O2SPureza:98.6%Forma y color:SolidPeso molecular:284.33(S)-Enitociclib
CAS:<p>(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that inhibits the transcription of anti-apoptotic and pro-survival proteins.</p>Fórmula:C19H18F2N4O2SPureza:98.98%Forma y color:SolidPeso molecular:404.43CLK-IN-T3
CAS:<p>CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.</p>Fórmula:C28H30N6O2Pureza:99.61%Forma y color:SolidPeso molecular:482.58(S)-PF-06873600
CAS:<p>(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.</p>Fórmula:C20H27F2N5O4SPureza:98.59%Forma y color:SolidPeso molecular:471.52CDK9-IN-10
CAS:<p>CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.</p>Fórmula:C22H16O5Pureza:99.8%Forma y color:SolidPeso molecular:360.36PS423
CAS:<p>PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.</p>Fórmula:C25H23F3O9Pureza:98.81% - 99.26%Forma y color:SolidPeso molecular:524.44HTH-01-091
CAS:<p>HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM).HTH-01-091 inhibits PIM1/2/3, RIPK2, DYRK3,</p>Fórmula:C26H28Cl2N4O2Pureza:98.4%Forma y color:SolidPeso molecular:499.43hSMG-1 inhibitor 11e
CAS:<p>hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.</p>Fórmula:C26H27N7O3SPureza:99.89%Forma y color:SolidPeso molecular:517.6CDK-IN-2
CAS:<p>CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).</p>Fórmula:C18H19ClFN3O2Pureza:99.67%Forma y color:SolidPeso molecular:363.819-Isopropylolomoucine
CAS:<p>9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.</p>Fórmula:C17H22N6OPureza:99.82%Forma y color:SolidPeso molecular:326.4CDK8-IN-1
CAS:<p>CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).</p>Fórmula:C11H8F3N3OPureza:98.48%Forma y color:SolidPeso molecular:255.2Cdc7-IN-7c
CAS:<p>Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.</p>Fórmula:C15H17N5OSPureza:98.19% - 99.22%Forma y color:SolidPeso molecular:315.39SEL120-34A
CAS:<p>SEL120-34A inhibits CDK8 (IC50: 4.4 nM) & CDK19 (10.4 nM), less on CDK9 (1070 nM), has antitumor properties.</p>Fórmula:C15H18Br2N4Pureza:99.764% - 99.84%Forma y color:SolidPeso molecular:414.14CDK4/6/1 Inhibitor
CAS:<p>CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).</p>Fórmula:C28H30F2N6Pureza:99.26% - 99.72%Forma y color:SolidPeso molecular:488.57BML-259
CAS:<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>Fórmula:C14H16N2OSPureza:99.84%Forma y color:SolidPeso molecular:260.35dCeMM2
CAS:<p>dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.</p>Fórmula:C16H11ClN6OSPureza:99.68%Forma y color:SolidPeso molecular:370.82Cdk2 Inhibitor II
CAS:<p>Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.</p>Fórmula:C14H11BrN4O3SPureza:97.07%Forma y color:SolidPeso molecular:395.23Abemaciclib metabolite M20
CAS:<p>Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂，可用于癌症治疗的相关研究。</p>Fórmula:C27H32F2N8OPureza:98.1% - 99.08%Forma y color:SolidPeso molecular:522.59SHP2/CDK4-IN-1
CAS:<p>SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.</p>Fórmula:C33H35ClF2N10OSForma y color:SolidPeso molecular:693.21CDK-IN-11
CAS:<p>CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].</p>Fórmula:C25H21BrN4O2Forma y color:SolidPeso molecular:489.36CDK/HDAC-IN-3
CAS:<p>CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,</p>Fórmula:C24H18Cl2N6O3Pureza:98%Forma y color:SolidPeso molecular:509.34Cdk4 Inhibitor
CAS:<p>PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.</p>Fórmula:C20H10BrN3O2Forma y color:SolidPeso molecular:404.2EHT 5372
CAS:<p>EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.</p>Fórmula:C17H11Cl2N5OSForma y color:SolidPeso molecular:404.27Nε-(1-Carboxyethyl)-L-lysine
CAS:<p>Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.</p>Fórmula:C9H18N2O4Forma y color:SolidPeso molecular:218.25Lerociclib
CAS:<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Fórmula:C26H34N8OPureza:99%Forma y color:SolidPeso molecular:474.6CDK8-IN-3
CAS:<p>CDK8-IN-3 is an inhibitor of CDK8.</p>Fórmula:C22H23N5O2Pureza:98%Forma y color:SolidPeso molecular:389.45CDK9-IN-29
CAS:<p>CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.</p>Fórmula:C29H33F2N5O4Pureza:98%Forma y color:SolidPeso molecular:553.6IIIM-290
CAS:<p>IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).</p>Fórmula:C23H21Cl2NO5Pureza:98%Forma y color:SolidPeso molecular:462.32CCT-251921
CAS:<p>CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).</p>Fórmula:C21H23ClN6OPureza:99.07%Forma y color:SolidPeso molecular:410.9CDK9-IN-8
CAS:<p>CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).</p>Fórmula:C31H32FN7O3Pureza:99.54%Forma y color:SolidPeso molecular:569.63QR-6401
CAS:<p>QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/</p>Fórmula:C19H23N5O3Pureza:98%Forma y color:SolidPeso molecular:369.42Tacaciclib
CAS:<p>Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].</p>Fórmula:C30H36N6O3Pureza:98%Forma y color:SolidPeso molecular:528.65Mevociclib
CAS:<p>Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.</p>Fórmula:C31H35ClN8O2Pureza:98.02% - 98.02%Forma y color:SolidPeso molecular:587.11Palbociclib orotate
CAS:<p>Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.</p>Fórmula:C29H33N9O6Pureza:98%Forma y color:SolidPeso molecular:603.63KM05382
CAS:<p>KM05382 inhibits CDK9 and the transcription of GAPDH.</p>Fórmula:C20H19ClN2O3S2Forma y color:SolidPeso molecular:434.96CDK4-IN-2
CAS:<p>CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].</p>Fórmula:C22H26F2N6O4SPureza:98%Forma y color:SolidPeso molecular:508.54DCB-3503
CAS:<p>DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.</p>Fórmula:C24H27NO5Forma y color:SolidPeso molecular:409.47LDC3140
CAS:<p>LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).</p>Fórmula:C23H33N7OPureza:98%Forma y color:SolidPeso molecular:423.55Leucettinib-92
CAS:<p>Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM</p>Fórmula:C21H22N4OSPureza:98%Forma y color:SolidPeso molecular:378.49CDK9-IN-9
CAS:<p>CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).</p>Fórmula:C22H23F2N5O2SPureza:98%Forma y color:SolidPeso molecular:459.51(2S,3R)-Voruciclib
CAS:<p>(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.</p>Fórmula:C22H19ClF3NO5Pureza:98%Forma y color:SolidPeso molecular:469.84CDK9-IN-2
CAS:<p>CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.</p>Fórmula:C23H25ClFN5Pureza:99%Forma y color:SolidPeso molecular:425.93CDK7-IN-14
CAS:<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Fórmula:C22H24F3N6OPForma y color:SolidPeso molecular:476.435-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Fórmula:C16H10IN3O2Forma y color:SolidPeso molecular:403.17NU6300
CAS:<p>NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.</p>Fórmula:C20H23N5O3SPureza:96.08%Forma y color:SolidPeso molecular:413.49Voruciclib hydrochloride
CAS:<p>Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).</p>Fórmula:C22H20Cl2F3NO5Pureza:98%Forma y color:SolidPeso molecular:506.3PF-6808472
CAS:<p>PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.</p>Fórmula:C25H27FN8O3SPureza:99.02%Forma y color:SolidPeso molecular:538.6CDK7-IN-22
CAS:<p>CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].</p>Fórmula:C22H25F3N6Pureza:98%Forma y color:SolidPeso molecular:430.47
